- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00453765
The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity (montelukast)
Prospective Single-centre, Double Blind Randomised Trial of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic cough is a frequent problem in general practice and one of the most common reasons for referral to a respiratory clinic. Prospective studies have shown that the vast majority of cases of chronic cough are due to one or more of three conditions: rhinitis/postnasal drip syndrome, asthma and gastro-oesophageal reflux disease. Other significant causes of chronic cough include postviral (post-infectious) cough, and eosinophilic bronchitis. In only a minority of the patients with a chronic cough no cause can be found. This is called idiopathic cough.
Analysis and treatment of patients with chronic cough often proved to be difficult and disappointing. Nevertheless, centers in which a comprehensive diagnostic and therapeutic protocol was implemented reported excellent results. Therefore the first cough clinic is started in The Isala Klinieken, Zwolle/The Netherlands in 2004.
Asthmatic cough is often accompanied by the more typical symptoms of dyspnoea and wheezing. In a subgroup of asthmatics, however, cough is the sole or predominant symptom. This condition is termed cough-variant asthma (CVA). Cough due to CVA usually improves within the first week of inhaled bronchodilator therapy, however, complete resolution of cough may require up to 8 weeks of combination therapy with inhaled bronchodilators and corticosteroids. A subgroup of CVA patients with severe, refractory cough may require systemic (oral) steroids, alone or followed by inhaled therapy.
Leukotrienes are contributing significantly to the pathobiology of asthma. These 'pathways of asthma' could be suppressed by leukotriene inhibitors. Multiple clinical trials have demonstrated the ability of the leukotriene modifiers to improve symptoms, pulmonary function and bronchial hyperresponsiveness in chronic asthma, as well as in exercise-induced and aspirin-induced asthma. Until recently, the antitussive effects of this drug class had not been investigated properly. Spector and Tan concluded in a pilot trial with only 14 patients that 10 mg montelukast seems to be effective in CVA. However, nowadays in care of asthma, montelukast is widely used in a dosage of 10 mg. Therefore we intend to study the effects of montelukast on chronic cough (VAS-cough-score) on a wider patient population; is montelukast superior to placebo in the treatment of patients with chronic cough and a demonstrated bronchial hyperreactivity?
Aim of the study:
The purpose is to determine whether montelukast during 6 weeks has superior antitussive effects (measured with the VAS cough) compared with placebo in patients with cough lasting > 8 weeks and enhanced bronchial hyperreactivity.
Study design:
Montelukast trial: prospective single-centre, double blind randomised trial.
In the montelukast study 84 patients between 18 and 90 years old, referred to the cough outpatient clinic with chronic cough and enhanced bronchial hyperreactivity will be recruited after informed consent is obtained.
Patients will be randomised (for gender, age, smoking, duration of symptoms and the use of inhaled corticosteroids) to 6- week treatment with 10 mg daily montelukast or placebo. Before randomisation all patients have to fill in the Visual Analogue Scale (VAS) for detection of the degree of cough in the last 24 hours and the dutch version of the Leicester Cough Questionnaire (LCQ) for the detection of illness specific quality of life. Adverse events will be noted in this period. Finally, both groups will be compared.
Inhaled corticosteroids may be continued during the study at a constant dose. Nasal, ophthalmologic and dermatological steroids are allowed according to individual needs, but their dose should be kept constant throughout the trial.
H1 blockers, nasal anticholinergics as well as nasal or ophthalmologic preparations of nedocromil or cromoglycate are permitted for treatment of allergic rhinitis.
Study population:
Patients between 18 and 90 years old, referred to the cough outpatient clinic with chronic cough and enhanced bronchial hyperreactivity.
Intervention:
Patients between 16 and 90 years old, referred to the cough outpatient clinic with chronic cough and enhanced bronchial hyperreactivity will receive daily montelukast 10 mg or placebo during 6 weeks.
Main study endpoint :
1. Difference in cough VAS scores; montelukast vs placebo.
Secondary study endpoints:
- Difference in average score on the Leicester Cough Questionaire (LCQ) between the two treatment groups; montelukast vs placebo.
- Comparison of the adverse events of montelukast vs placebo.
Randomisation:
Patients will be randomised by a computer minimisation program for the following factors: gender, age, smoking, duration of symptoms and the use of inhaled corticosteroids.
Statistical analysis:
The primary analysis will be on an intention-to-treat basis. The mean change in the primary endpoint (LCQ total and domain scores) after 6 weeks between the groups will be analysed using an unpaired t-test. This test will also be used to analyse differences after 6 weeks in secondary endpoints (VAS cough score).
Since both the primary and secondary endpoints in the study will be measured more than two times (repeatedly measured) the course of these scores over time will be tested using MANOVA-analysis. To test for differences in proportions (proportion of patients with adverse events) the Chi2 -test will be used. Data analyses will be performed using SPSS version 12.
Burden, risks and advantages associated with participation:
Side effects have been reported in 10 % of the cases; mostly of headache and abdominal pain. Also gastrointestinal problems, allergic reactions, psychiatric disorders, liver, and haematological disorders could occur.
Interactions: Montelukast is metabolised by CYP3A4. Concomitant use of CYP3A4 inducing medication like fenytoïne, phenobarbital, or rifampicin must be prevented.
Medication metabolised by CYP2C8 must also be avoided, because in vitro studies have shown that montelukast is an powerful CYP2C8 inhibitor.
Benefits: superior resolution of cough compared to placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Zwolle, Netherlands, 8011 JW
- Isala Klinieken
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients between 18 and 90 years old, referred to the cough outpatient clinic with chronic cough and enhanced bronchial hyperreactivity.
- chronic cough is defined as a cough > 8 weeks duration.
- enhanced bronchial hyperreactivity is a PD20 < 2.5 mg methacholine.
Exclusion Criteria:
- concomitant severe disease; lung cancer and diseases with a short life expectancy (< 1 year).
- patients suffering from COPD and/or other relevant lung diseases.
- clinically relevant abnormal laboratory values suggesting an unknown disease requiring further clinical evaluation.
- use of systemic steroids 4 weeks (injectable depot steroids 6 weeks) before entry into the baseline period, or more than 3 courses during the last 6 months.
- pregnancy.
- abnormal chest X-ray.
- use of medication inducing CYP3A4 (for example; fenytoïne, phenobarbital or rifampicin.
- use of medication metabolised by CYP2C8.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: B
placebo
|
placebo
|
Experimental: A
montelukast
|
montelukast, 8 weeks, once daily, 10 milligrams
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in average score on the Leicester Cough Questionnaire (LCQ) between the two treatment groups; montelukast vs placebo.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in cough VAS scores; montelukast vs placebo.
Time Frame: 2 years
|
2 years
|
Comparison of the adverse events of montelukast vs placebo.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jan Willem Van Den Berg, MD, Departement of Pulmonology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Bronchial Diseases
- Signs and Symptoms, Respiratory
- Cough
- Bronchial Hyperreactivity
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- NL14828.075.06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
The First Affiliated Hospital of Zhejiang Chinese...Completed
-
ILiAD BiotechnologiesCompletedPertussis/Whooping Cough | Bordetella Pertussis, Whooping CoughUnited Kingdom
-
KK Women's and Children's HospitalSingapore University of Technology and DesignUnknownCough | URTI | Cough Variant Asthma | Cough; Bronchial, With Grippe or InfluenzaSingapore
-
Shanghai Zhongshan HospitalNot yet recruitingSufentanil-induced Cough
-
Merck Sharp & Dohme LLCCompletedChronic CoughCanada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
-
Khon Kaen UniversityCompleted
-
PhytoHealth CorporationCompleted
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States